Shionogi to buy US drugmaker IntraBio for $2B in rare-disease push
What's the deal? Japanese pharmaceutical company ShionogiDealroom has a profile for this one. Try Dealroom → said Monday it will acquire all shares in US drugmaker IntraBio for $2 billion. The deal adds IntraBio's rare-disease drug Aqneursa, along with its global intellectual property and commercialisation rights, to Shionogi's portfolio.
Why now? The acquisition is expected to close between November and December 2026. It remains subject to competition-law waiting periods and regulatory approvals in relevant countries.
What's the endgame? For Shionogi, a publicly listed pharmaceutical company, the purchase expands its presence in rare diseases. Gaining worldwide rights to Aqneursa gives it a commercial product with global reach.
The signal: The deal marks another instance of a large Japanese drugmaker buying a smaller US specialist to broaden its pipeline. Rare-disease treatments remain a target for pharmaceutical companies seeking growth outside crowded therapeutic areas.
Read more: mlex.com
Image credit: Generated with Gemini
